Investigational drug · Phase 2
ABSK141
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumors, Adult.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ABSK141"
First trial start
2026
Mar 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABSK141", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors, Adult
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ABSK141" as an intervention, largest first.
Abbisko Therapeutics Co, LtdIndustry
NCT07417189 · 401 participants (planned) · Start Mar 2, 2026 · Primary completion Dec 30, 2028
Drug: ABSK141-400mg; ABSK141-Recommended Dose for Expansion (RDE) and 3 more · For: Solid Tumors, Adult
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumors, Adult
- TersolisibLY4064809, STX-478Phase 33 trials
Eli Lilly · Breast Neoplasms, Neoplasm Metastasis, Breast Cancer
- RDEABSK141-Recommended Expansion, S095018 RecommendedPhase 22 trials
Abbisko Therapeutics Co, Ltd · Solid Tumors, Adult, Non-small Cell Lung Cancer (NSCLC)
- TNG260Phase 21 trial
Tango Therapeutics, Inc. · Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.